Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol

The Journal of Pathology (Impact Factor: 7.43). 12/2004; 204(5):569 - 577. DOI: 10.1002/path.1666


The NF-κB family of transcription factors regulates a wide variety of cellular processes including cell growth, differentiation, and apoptosis. A tissue microarray was constructed from paraffin wax-embedded blocks from 95 endometrial carcinomas (EC), previously studied for microsatellite instability, as well as for alterations in PTEN, k-RAS and beta-catenin. Immunohistochemical evaluation included members of the NF-κB (p50, p65, p52, c-Rel, Rel-B) and the IκB (IκBα, IκBβ, IκBε, Bcl-3) families, as well as putative targets of NF-κB such as Flip, Bcl-xL, Cyclin D1, and oestrogen and progesterone receptors. Results were correlated with the clinical and pathological data. Nuclear immunostaining for members of the NF-κB family was frequent in EC (p50, 20%; p65, 16.5–21.9%; p52, 9.3%; c-Rel, 48.9%; Rel-B, 15.7%); and it correlated with negativity for members of the IκB family in some cases. There was a statistically significant association between immunoreaction for p50 and p65 (p = 0.006), suggesting activation of the so-called ‘classic form’ of NF-κB, similar to that described in breast cancer. Bcl-3 nuclear immunostaining was detected in 60.7% of cases. The vast majority of p52-positive tumours showed Bcl-3 nuclear immunoreaction (p = 0.038). Immunostaining for putative targets of NF-κB was as follows: Bcl-xL, 76.2% (p = 0.001); Flip 43.0%; Cyclin D1, 64.79%. p65 immunostaining correlated with increased immunoreaction for steroid hormone receptors. No correlation was found between NF-κB nuclear pattern and the presence of microsatellite instability, or alterations in PTEN, k-RAS, or beta-catenin. These results suggest that the NF-κB and IκB families of genes may be important in endometrial carcinogenesis, by controlling apoptosis and cell proliferation. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Download full-text


Available from: David Llobet-Navas, May 31, 2014
20 Reads
  • Source
    • "In contrast, Type 2 tumors are associated with p53 and ERBB-2 (HER-2/neu) mutations and loss of heterozygosity on several chromosomes , and in most cases are not diploid [7] [8] [9]. Systemic hormonal and chemotherapeutic treatments represent the cornerstones of advanced and recurrent endometrial cancer management , although it is still characterized by a poor prognosis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study evaluated the potential ability of MK-0646 to inhibit IGF1-mediated biological actions and cell signaling events in Type 1 and Type 2 endometrial cancer. We found that MK-0646 treatment significantly decreased IGF1R expression. In addition, pretreatment with MK-0646 decreased the IGF1-induced phosphorylation of IGF1R, AKT and ERK. Apoptosis analyses showed that MK-0646 abolished the anti-apoptotic effect of IGF1. Furthermore, MK-0646 treatment abolished the IGF1-stimulatory effect on proliferation and enhanced the cytotoxic effect of cisplatin. These findings indicate that specific inhibition of IGF1R could be a useful therapeutic approach for Type 1 and Type 2 endometrial cancer.
    Cancer letters 02/2013; 335(1). DOI:10.1016/j.canlet.2013.02.009 · 5.62 Impact Factor
  • Source
    • "This effect is mediated by its association with the NF-kappa B homodimers, p50 and p52, along with coactivators such as CBP/p300, SRC-1 and Tip60 [4,6]. While Bcl-3 overexpression was originally found to be associated with CLL and lymphomas, recent reports have shown that this oncogene is overexpressed in several solid tumors, such as breast [7], nasopharyngeal [8] and endometrial [9] carcinomas. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bcl-3 is an atypical member of the inhibitor of NF-kappa B family of proteins since it can function as a coactivator of transcription. Although this oncogene was described in leukemia, it is overexpressed in a number of solid tumors as well. The oncogenic potential of Bcl-3 has been associated with its capacity to increase proliferation by means of activating the cyclin D1 promoter and to its antiapoptotic role mediated by the inhibiton of p53 activity. In the course of dissecting these properties, we found that depleting Bcl-3 protein using shRNAs induce a decrease of proliferation and clonogenic survival associated with the induction of multinucleation and increased ploidy. These effects were associated with a DNA damage response, a delay in G2/M checkpoint and the induction of centrosome amplification.
    Molecular Cancer 08/2010; 9(1):223. DOI:10.1186/1476-4598-9-223 · 4.26 Impact Factor
  • Source
    • "Here, we found the NF-κB subunit RelA to be overexpressed in roughly half of a large set of pancreatic adenocarcinomas analysed. Overexpression of cytoplasmic and/or nuclear RelA in tumour tissue has been previously observed in larger study cohorts of gastric (Sasaki et al, 2001; Yamanaka et al, 2004; Cao et al, 2005; Lee et al, 2005), prostate (Fradet et al, 2004; Ismail et al, 2004; Ross et al, 2004; Shukla et al, 2004; Sweeney et al, 2004), endometrial (Pallares et al, 2004), hepatocellular (Tai et al, 2000) and oral (Nakayama et al, 2001) as well as cervical (Nair et al, 2003) carcinoma. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Activation of nuclear factor-kappaB (NF-kappaB) signaling was observed in pancreatic adenocarcinoma cell lines and tumours. However, information on the expression of RelA/p65, the major transcription activating NF-kappaB subunit, in these carcinomas and possible correlations thereof with NF-kappaB activation and patient survival is not available. To provide this missing translational link, we analysed expression of RelA/p65 in 82 pancreatic adenocarcinomas by immunohistochemistry. Moreover, we measured activation of the NF-kappaB pathway in 11 tumours by quantitative PCR for NF-kappaB target genes. We observed strong cytoplasmic or nuclear expression of RelA/p65 in 42 and 37 carcinomas, respectively. High cytoplasmic and nuclear expression of RelA/p65 had negative prognostic impact with 2-year survival rates for patients without cytoplasmic or nuclear RelA/p65 positivity of 41 and 40% and rates for patients with strong cytoplasmic or nuclear RelA/p65 expression of 22 and 20%, respectively. High RelA/p65 expression was correlated to increased expression of NF-kappaB target genes. The observation that high expression of RelA/p65 is correlated to an activation of the NF-kappaB pathway and indicates poor patient survival identifies a patient subgroup that might particularly benefit from NF-kappaB-inhibiting agents in the treatment of pancreatic cancer. Based on our findings, this subgroup could be identified by applying simple immunohistochemical techniques.
    British Journal of Cancer 09/2007; 97(4):523-30. DOI:10.1038/sj.bjc.6603878 · 4.84 Impact Factor
Show more